| 达纳康治疗血管性认知功能损害的临床研究 |
| |
| 引用本文： | 刘汉兴,章军建,黄朝云,杨四清. 达纳康治疗血管性认知功能损害的临床研究[J]. 卒中与神经疾病, 2004, 11(2): 101-103 |
| |
| 作者姓名： | 刘汉兴 章军建 黄朝云 杨四清 |
| |
| 作者单位： | 430071,武汉大学中南医院神经科 |
| |
| 摘 要： | 目的评价达纳康(Egb761)治疗血管性认知功能障碍的临床疗效和安全性.方法110例血管性认知功能损害的病人随机分配到治疗组和对照组;治疗组服用达纳康,每次80 mg,每日3次,而对照组服用丹参片,每次2片,每日3次,疗程均为3个月,并应用MMSE和ADL量表评价其疗效.结果治疗组MMSE评分增加较对照组多2.38,差异有统计学意义(P＜0.01);治疗组ADL评分减少较对照组多0.41,但差异无统计学意义(P＞0.05)结论达纳康治疗血管性认知功能损害安全有效.
|
| 关 键 词： | 达纳康 血管性认知功能损害 临床研究 |
| 文章编号： | 1007-0478(2004)02-0101-03 |
A clinical study of Tanakan in the vascular cognitive impairment |
| |
| Liu Hanxing,Zhang Junjian,Huang Chaoyun,et al.. A clinical study of Tanakan in the vascular cognitive impairment[J]. Stroke and Nervous Diseases, 2004, 11(2): 101-103 |
| |
| Authors: | Liu Hanxing Zhang Junjian Huang Chaoyun et al. |
| |
| Affiliation: | Liu Hanxing,Zhang Junjian,Huang Chaoyun,et al. Department of Neurology,Zhongnan Hospital,Wuhan University,Wuhan 430071 |
| |
| Abstract: | Objective To assess the efficacy and safety of Tanakan in vascular cognitive impairment(VCI). Methods One hundred and ten patients with VCI were assigned randomly to treatment with Tanakan or Dan-shen. The test group was treated with Tanakan (80 mg Tid) and the control group was treated with Dan-shen (2 tables Tid). The duration of therapy was three months, MMSE and ADL were used to measure outcome. Results The Tanakan group had a MMSE score 2.38 points better than the Dan-shen group (P < 0.01) and an ADL score 0.41 points lower than the Dan-shen group (P >0.05). There was significant differenc between Tanakan group and Dan-shen group in VCI. Conclusions Tanakan is safe and appears capable of improving the cognitive performance of VCI patients. |
| |
| Keywords: | Tanakan Vascular cognitive impairment Clinical study |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
